FXTM information and reviews
OctaFX information and reviews
XM information and reviews
FXCC information and reviews
HFM information and reviews
FxPro information and reviews

Pfizer stock rockets after $43 billion acquisition of Seagen

27 March 2023

Pfizer (PFE) has announced that it will acquire Seagen for the sum of $43 billion (USD). The deal is expected to close in late 2023 or early 2024, pending regulatory approvals and other customary closing conditions, but that’s a long time away in the trading term. What can we expect to see on the charts in the coming months?

Who is Seagen?

Seagen is known for its antibody-drug conjugate (ADC) technology, which delivers potent drugs directly to cancer cells while sparing healthy tissues. Seagen has three approved products on the market: Adcetris, Padcev, and Tukysa. It also has a robust pipeline of more than 10 clinical-stage candidates across various types of cancers.

Pfizer said that the acquisition of Seagen would enhance its oncology portfolio and capabilities, as well as accelerate its revenue growth and earnings potential. But could such a purchase increase share value in 2023, since Pfizer itself only expects the deal to be accretive to its adjusted earnings per share by 2025?

Pfizer's CEO Albert Bourla said in a statement: "We are thrilled to welcome Seagen to the Pfizer family and believe that together we will transform the lives of millions of cancer patients around the world. Seagen's expertise in ADC complements our leadership in immuno-oncology and targeted therapies, creating an unrivaled opportunity to advance the science and deliver more breakthroughs for patients."

Until now, Pfizer has only focused on Covid vaccination, antibiotics, and supplements. Moving into the cancer treatment sector opens many doors for the company with a potential long-term supply/demand dynamic.

Seagen's CEO Clay Siegall said in a statement: "We are proud of what we have accomplished at Seagen over the past two decades and are excited to join forces with Pfizer to bring our innovative medicines to more patients globally. We share a common vision of discovering and developing transformative therapies for people with cancer."

How will Pfizer stock react to this news? Some analysts have expressed positive views on the deal. For example, Mizuho Securities analyst Vamil Divan said: "We view this as an attractive acquisition for Pfizer given Seagen's strong position in hematology/oncology. We also see significant synergies from combining Pfizer's global reach with Seagen's innovative pipeline."

Before Pfizer announced the Seagen acquisition on 13 March 2023, Pfizer's stock tanked due to an unexplainable selloff. After the acquisition news confirmed the offer of $229 (USD) per Seagen share, the market sentiment became strongly bullish, rising 7% to $40.65  within the first 5 hours. Now in a steady range rise, the latest retrace barely made it to the 0.236 of the Fibonacci, making it a strong bullish signal.

However, some investors may have concerns about the high price tag of the deal, which values Seagen at a premium of about 40% over its closing price on Friday. Some may also question whether Pfizer can integrate Seagen smoothly and efficiently without disrupting its operations. And of course, the looming recession is still a factor to consider.


Ultimately, the long-term impact of the deal will depend on how well Pfizer can leverage Seagen's assets and expertise to create value for its shareholders and customers. Covid was a convenient cash cow for the pharmaceutical giant, and now it is turning its sights on Cancer, and if it makes significant advances in treatments and success rates, the sky's the limit.

And while the joining of these two companies will be beneficial to millions over the coming years, Q2 traders might consider adding stochastic and RSI to their chart analysis when forecasting with technicals. A steady growth seems obvious, but increased trading volume from institutional investors may be sporadic, causing wild and unforeseeable volatility. Exness’ Stop Out Protection feature will significantly reduce risks, but Stop Loss is highly recommended for traders planning to leave orders open for multiple days or weeks.


Share: Tweet this or Share on Facebook


Global Stock Market Prediction: EU, Asia, and Turkey
Global Stock Market Prediction: EU, Asia, and Turkey

The global stock market has been a hot topic of discussion recently, with investors closely monitoring various regional markets and seeking stock market predictions. This article will delve into the performance of European...

31 May 2023

Stock Market Predictions 2023: Analyzing Opportunities
Stock Market Predictions 2023: Analyzing Opportunities

Are you eager to navigate the twists and turns of the stock market and make informed investment decisions? Look no further than the Singapore Stock Exchange and the enticing realm of Chinese equities...

31 May 2023

TOP 5 investments in 2023
TOP 5 investments in 2023

When choosing an investment strategy, start by setting your financial goals and determining your risk tolerance. You simply select a portfolio with an acceptable risk profile. One of the main rules when choosing a strategy...

30 May 2023

Stock Market Predictions: A Strong Market Recovery
Stock Market Predictions: A Strong Market Recovery

As investors continue to navigate the dynamic landscape of the stock market, stock market predictions become paramount in making informed decisions...

29 May 2023

EUR/USD continues to face downward pressure
EUR/USD continues to face downward pressure

During the mid-Asian session, the EUR/USD pair continues to face downward pressure, with Euro bears taking a pause after reaching the lowest levels since late March...

26 May 2023

Stock Market Sectors: EU Markets Down, UK Inflation Falls
Stock Market Sectors: EU Markets Down, UK Inflation Falls

In the world of finance, the stock market sectors play a pivotal role in shaping investment strategies. As European markets experience a downward trend due to stumbling US debt ceiling talks...

25 May 2023

Editors' Picks

FXCM information and reviews
MultiBank Group information and reviews
MultiBank Group
RoboForex information and reviews
Libertex information and reviews
Vantage information and reviews
FP Markets information and reviews
FP Markets

© 2006-2023 Forex-Ratings.com

The usage of this website constitutes acceptance of the following legal information.
Any contracts of financial instruments offered to conclude bear high risks and may result in the full loss of the deposited funds. Prior to making transactions one should get acquainted with the risks to which they relate. All the information featured on the website (reviews, brokers' news, comments, analysis, quotes, forecasts or other information materials provided by Forex Ratings, as well as information provided by the partners), including graphical information about the forex companies, brokers and dealing desks, is intended solely for informational purposes, is not a means of advertising them, and doesn't imply direct instructions for investing. Forex Ratings shall not be liable for any loss, including unlimited loss of funds, which may arise directly or indirectly from the usage of this information. The editorial staff of the website does not bear any responsibility whatsoever for the content of the comments or reviews made by the site users about the forex companies. The entire responsibility for the contents rests with the commentators. Reprint of the materials is available only with the permission of the editorial staff.
We use cookies to improve your experience and to make your stay with us more comfortable. By using Forex-Ratings.com website you agree to the cookies policy.